Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Galmed Pharmaceutica (GLMD)

Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,963
  • Shares Outstanding, K 644
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,910 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 0.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.25
  • Growth Rate Est. (year over year) +44,500.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.56 +19.14%
on 12/05/24
3.39 -10.03%
on 12/17/24
+0.09 (+3.04%)
since 11/20/24
3-Month
2.56 +19.14%
on 12/05/24
11.19 -72.74%
on 09/23/24
-6.30 (-67.38%)
since 09/20/24
52-Week
2.56 +19.14%
on 12/05/24
23.80 -87.18%
on 09/17/24
-1.75 (-36.43%)
since 12/20/23

Most Recent Stories

More News
Galmed Pharmaceuticals: Q3 Earnings Snapshot

Galmed Pharmaceuticals: Q3 Earnings Snapshot

GLMD : 3.05 (-0.65%)
MarketBeat Week in Review – 9/16 - 9/20

Stocks got a boost as the Federal Reserve cut interest rates, but investors should expect more volatility as economic data continues to deliver mixed signals

NVDA : 134.70 (+3.08%)
GOOGL : 191.41 (+1.54%)
AAPL : 254.49 (+1.88%)
MU : 90.12 (+3.48%)
ZG : 73.77 (+2.97%)
COIN : 278.71 (+1.75%)
DAL : 60.93 (+0.91%)
ASTS : 22.88 (-0.52%)
MSFT : 436.60 (-0.10%)
SHOP : 108.95 (+1.76%)
BYND : 3.55 (+4.11%)
MA : 528.03 (+0.91%)
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
MRK : 98.05 (-1.48%)
NVS : 97.11 (+0.35%)
ONC.TO : 1.19 (-9.16%)
GLMD : 3.05 (-0.65%)
PFE : 26.36 (+2.29%)
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

ONCY : 0.8310 (-6.36%)
MRK : 98.05 (-1.48%)
NVS : 97.11 (+0.35%)
ONC.TO : 1.19 (-9.16%)
GLMD : 3.05 (-0.65%)
PFE : 26.36 (+2.29%)
Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion?

Galmed Pharmaceuticals (NASDAQ: GLMD) stock skyrocketed nearly 400%, trading over 80 million shares, compared to its average of 75,000.

GLMD : 3.05 (-0.65%)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 1.0400 (-48.00%)
GLMD : 3.05 (-0.65%)
VKTX : 42.25 (+1.83%)
ETNB : 7.94 (+12.94%)
IVA : 2.35 (-0.84%)
SGMT : 4.95 (-2.37%)
TERN : 5.86 (-3.14%)
NVO : 85.00 (-17.83%)
IQV : 197.27 (+3.00%)
MDGL : 308.44 (+5.12%)
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 3.05 (-0.65%)
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

/PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 3.05 (-0.65%)
Galmed Pharmaceuticals: Q2 Earnings Snapshot

Galmed Pharmaceuticals: Q2 Earnings Snapshot

GLMD : 3.05 (-0.65%)
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

/PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and...

GLMD : 3.05 (-0.65%)

Business Summary

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel.

See More

Key Turning Points

3rd Resistance Point 3.71
2nd Resistance Point 3.51
1st Resistance Point 3.28
Last Price 3.05
1st Support Level 2.85
2nd Support Level 2.66
3rd Support Level 2.43

See More

52-Week High 23.80
Fibonacci 61.8% 15.69
Fibonacci 50% 13.18
Fibonacci 38.2% 10.67
Last Price 3.05
52-Week Low 2.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar